ProQR Therapeutics N.V Operating Expenses Growth & History (PRQR)
ProQR Therapeutics N.V's operating expenses was €59.8M for fiscal 2025.
View full ProQR Therapeutics N.V company overviewProQR Therapeutics N.V annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €59.8M | €9.8M | +19.55% |
| 2024 | 2024-12-31 | €50.0M | €8.6M | +20.86% |
| 2023 | 2023-12-31 | €41.4M | −€28.1M | −40.47% |
| 2022 | 2022-12-31 | €69.5M | €9.9M | +16.66% |
| 2021 | 2021-12-31 | €59.6M | €7.8M | +14.99% |
| 2020 | 2020-12-31 | €51.8M | −€7.6M | −12.73% |
| 2019 | 2019-12-31 | €59.4M | €17.3M | +41.19% |
| 2018 | 2018-12-31 | €42.1M | €61,000 | +0.15% |
| 2017 | 2017-12-31 | €42.0M | €592,000 | +1.43% |
| 2016 | 2016-12-31 | €41.4M | €11.2M | +36.92% |
| 2015 | 2015-12-31 | €30.2M | — | — |
ProQR Therapeutics N.V quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €17.6M | €1.4M | +8.36% |
| Q1 2026 | 2026-03-31 | €15.7M | €125,000 | +0.80% |
| Q4 2025 | 2025-12-31 | €13.8M | −€711,000 | −4.90% |
| Q3 2025 | 2025-09-30 | €14.2M | €1.5M | +11.83% |
| Q2 2025 | 2025-06-30 | €16.2M | €6.2M | +61.26% |
| Q1 2025 | 2025-03-31 | €15.6M | €2.8M | +22.16% |
| Q4 2024 | 2024-12-31 | €14.5M | €2.0M | +16.35% |
| Q3 2024 | 2024-09-30 | €12.7M | €3.9M | +44.93% |
| Q2 2024 | 2024-06-30 | €10.1M | €7,000 | +0.07% |
| Q1 2024 | 2024-03-31 | €12.7M | €2.6M | +26.26% |
| Q4 2023 | 2023-12-31 | €12.5M | −€1.2M | −8.69% |
| Q3 2023 | 2023-09-30 | €8.8M | −€11.9M | −57.70% |
| Q2 2023 | 2023-06-30 | €10.1M | −€6.8M | −40.37% |
| Q1 2023 | 2023-03-31 | €10.1M | −€8.2M | −44.81% |
| Q4 2022 | 2022-12-31 | €13.7M | −€4.1M | −23.08% |
| Q3 2022 | 2022-09-30 | €20.7M | €5.0M | +31.79% |
| Q2 2022 | 2022-06-30 | €16.9M | €3.0M | +21.68% |
| Q1 2022 | 2022-03-31 | €18.3M | €6.0M | +49.26% |
| Q4 2021 | 2021-12-31 | €17.8M | €5.8M | +48.96% |
| Q3 2021 | 2021-09-30 | €15.7M | €4.6M | +41.41% |
| Q2 2021 | 2021-06-30 | €13.9M | €1.8M | +15.16% |
| Q1 2021 | 2021-03-31 | €12.2M | −€4.5M | −26.87% |
| Q4 2020 | 2020-12-31 | €11.9M | −€5.9M | −33.15% |
| Q3 2020 | 2020-09-30 | €11.1M | −€2.9M | −20.49% |
| Q2 2020 | 2020-06-30 | €12.0M | −€366,000 | −2.95% |
| Q1 2020 | 2020-03-31 | €16.7M | €1.6M | +10.49% |
| Q4 2019 | 2019-12-31 | €17.8M | — | — |
| Q3 2019 | 2019-09-30 | €14.0M | €5.1M | +57.47% |
| Q2 2019 | 2019-06-30 | €12.4M | €3.8M | +43.52% |
| Q1 2019 | 2019-03-31 | €15.2M | — | — |
| Q3 2018 | 2018-09-30 | €8.9M | — | — |
| Q2 2018 | 2018-06-30 | €8.6M | −€1.8M | −17.28% |
| Q2 2017 | 2017-06-30 | €10.4M | — | — |
ProQR Therapeutics N.V operating expenses trends
Over the last five fiscal years, ProQR Therapeutics N.V's operating expenses increased from €51.8M to €59.8M, a change of €8.0M. The latest reported quarter, Q2 2026, shows €17.6M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ProQR Therapeutics N.V source filings ↗